Systemic therapy for metastatic urothelial carcinoma
Journal
BJU International
Journal Volume
101
Journal Issue
7
Pages
795-803
Date Issued
2008
Author(s)
SDGs
Other Subjects
alpha interferon; anthracycline; carboplatin; cetuximab; cisplatin; docetaxel; doxorubicin; etoposide; fluoropyrimidine; fluorouracil; folinic acid; gefitinib; gemcitabine; ifosfamide; lapatinib; lonafarnib; methotrexate; navelbine; oxaliplatin; paclitaxel; panitumumab; pemetrexed; platinum; protein tyrosine kinase inhibitor; tipifarnib; trastuzumab; unindexed drug; vinblastine; vinflunine; add on therapy; bladder cancer; cancer combination chemotherapy; cancer surgery; cancer survival; cancer therapy; clinical trial; colorectal cancer; DNA repair; drug activity; drug efficacy; drug metabolism; drug potentiation; drug targeting; drug tolerability; excision repair; human; lung non small cell cancer; nephrotoxicity; neurotoxicity; neutropenia; priority journal; prognosis; protein expression; short survey; statistical significance; thrombocytopenia; transitional cell carcinoma; treatment response; urogenital tract carcinoma; urogenital tract tumor; vomiting; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Delivery Systems; Humans; Neoplasm Metastasis; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome; Urologic Neoplasms
Type
journal article